|
||
|
|
|
||
|
|
This Figure updates the previous Figure, [91][92][93] with the addition of the 2012 American College of Chest Physician Guidelines (ACCP). [94] as well as the 2012 Stroke Consensus Report, [95] both of which recommend the newer oral anticoagulants in preference to warfarin. The new direct thrombin inhibitor (DTI) dabigatran is listed as an alternative in preference to warfarin, but that was because these guidelines preceded the approval of the 2 newest NOACs in the new class of Factor Xa inhibitors, rivaroxaban and apixaban, and physicians should be aware of the newest agents in both classes.
Reiffel JA. Am J Med 2013; 126: 00-00.
[91] Fuster V, Rydén LE, Cannom DS, et al. 2011 ACCF/AHA/HRS Focused updates incorporated into fthe ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines Developed in partnership with the European Society of Cardiology and in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. J Am Coll Cardiol. 2011;57:e101-e198.
[92] Wann LS, Curtis AB, Ellenbogen KA, et al. 2011 ACCF/AHA/HRS focused update on the management of patients with atrial fibrillation (update on dabigatran): a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. J Am Coll Cardiol. 2011;57:1330-1337.
[93] Camm AJ, Lip GY, De Caterina R, et al; ESC Committee for Practice Guidelines (CPG),. 2012 focused update of the ESC guidelines for the management of atrial fibrillation: An update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. Eur Heart J. 2012;33:2719-2747.
[94] Lansberg MG, O'Donnell MJ, Khatri P, et al. Antithrombotic and thrombolytic therapy for ischemic stroke: Antithrombotic Therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141(2 Suppl):e601S-e636S.
[95] Furie KL, Goldstein LB, Albers GW, et al; the American Heart Association Stroke Council, Council on Quality of Care and Outcomes Research, Council on Cardiovascular Nursing, Council on Clinical Cardiology, and Council on Peripheral Vascular Disease. Oral antithrombotic agents for the prevention of stroke in nonvalvular atrial fibrillation: A Science Advisory for Healthcare Professionals from the American Heart Association/American Stroke Association. Stroke. 2012;43:3442-3453.